TickerFacts.

UL Solutions Inc. (ULS): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$1.51B
Year ended 2025-12-31
+7.8%
3-year compound annual growth
2022-12-31: $1.21B2023-12-31: $1.28B2024-12-31: $1.39B2025-12-31: $1.51B$1.51B
2022-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$1.51B+8.5%2026-02-19, From 2025-01-01
2024-12-31$1.39B+8.4%2026-02-19, From 2024-01-01
2023-12-31$1.28B+6.4%2026-02-19, From 2023-01-01
2022-12-31$1.21Bn/a2025-02-20, From 2022-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
UL Solutions Inc. (ULS)2025-12-31$1.51B+8.5%
Incyte Corp (INCY)2025-12-31$4.77B+21.4%
Icon PLC (ICLR)2024-12-31$2.34B+0.4%
NeoGenomics Inc (NEO)2025-12-31$314.29M+8.3%
MaxCyte, Inc. (MXCT)2025-12-31$26.80M-15.0%
20/20 Biolabs, Inc. (AIDX)2025-12-31$604.5K+67.8%
iSpecimen Inc. (ISPC)2025-12-31$24.1K-99.4%
OneMedNet Corp (ONMD)2025-12-31-$503.0Kn/m
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$262.9K+29.4%

Compare ULS, INCY, ICLR, NEO side by side · Screen every company in Services-Testing Laboratories ↗